Molecular structure of XL888, CAS Number: 1149705-71-4
XL888 (CAS 1149705-71-4)
Alternate Names:
N1-[(3-endo)-8-[5-(cyclopropylcarbonyl)-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-5-[[(1R)-1-methylpropyl]amino]-1,4-benzenedicarboxamide
CAS Number:
1149705-71-4
Molecular Weight:
503.6
Molecular Formula:
C29H37N5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
XL888 (CAS 1149705-71-4) References
- High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888. | Lyman, SK., et al. 2011. PLoS One. 6: e17692. PMID: 21408192
- The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. | Paraiso, KH., et al. 2012. Clin Cancer Res. 18: 2502-14. PMID: 22351686
- Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. | Bussenius, J., et al. 2012. Bioorg Med Chem Lett. 22: 5396-404. PMID: 22877636
- Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. | Haarberg, HE., et al. 2013. Mol Cancer Ther. 12: 901-12. PMID: 23538902
- XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. | Phadke, M., et al. 2015. J Invest Dermatol. 135: 2542-2544. PMID: 26039542
- The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox. | Vido, MJ. and Aplin, AE. 2015. J Invest Dermatol. 135: 2355-2357. PMID: 26358385
- Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. | Azimi, A., et al. 2018. Mol Syst Biol. 14: e7858. PMID: 29507054
- The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma. | Sun, C., et al. 2021. Life Sci. 282: 119762. PMID: 34186047
- An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis. | Lee, JY., et al. 2024. J Clin Invest. 134: PMID: 38451724
- Selective targeting of Plasmodium falciparum Hsp90 disrupts the 26S proteasome. | Mansfield, CR., et al. 2024. Cell Chem Biol. 31: 729-742.e13. PMID: 38492573
Inhibitor of:
ERK 1, and Integrin αX.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
XL888, 5 mg | sc-507309 | 5 mg | $260.00 |